Is standard troponin I screening useful in patients aged 65 years or older or with a Revised Cardiac Risk Index ≥ 1 undergoing major vascular or intermediate‑risk non‑cardiac surgery?

Postoperative Troponin Screening in High-Risk Surgical Patients

Yes, routine troponin I screening is useful and strongly recommended for patients aged ≥65 years or with RCRI ≥1 undergoing major vascular or intermediate-risk noncardiac surgery. Daily troponin measurements should be obtained for 48-72 hours postoperatively in this population 1.

Key Recommendation

The 2017 Canadian Cardiovascular Society guidelines provide the most definitive and recent recommendation: obtain daily troponin measurements for 48-72 hours after noncardiac surgery in patients with baseline risk >5% for cardiovascular death or nonfatal MI at 30 days 1. This specifically includes:

• Patients with RCRI score ≥1
• Age 45-64 years with significant cardiovascular disease
• Age ≥65 years or older (regardless of other risk factors)
• Patients with elevated preoperative NT-proBNP/BNP

This is a Strong Recommendation with Moderate-Quality Evidence 1.

Why This Matters for Mortality

The evidence supporting routine screening is compelling:

• 65% of perioperative myocardial infarctions are asymptomatic due to analgesic medications masking ischemic symptoms 1
• Asymptomatic MIs carry similar mortality risk as symptomatic ones (aOR 4.00 vs 4.76 for 30-day mortality) 1
• 84% of patients with myocardial injury after noncardiac surgery (MINS) remain asymptomatic and are only detected through routine surveillance 1
• MINS increases 30-day mortality from 1.1% to 9.8% 1
• Troponin elevation is the strongest predictor of 30-day mortality in the VISION study (N=15,133) 1

Divergence in Guidelines

Important caveat: The 2014 ACC/AHA guidelines take a more conservative stance, stating that routine screening in high-risk patients has uncertain usefulness (Class IIb) in the absence of established management strategies 2, 3. They explicitly recommend against routine screening in unselected patients (Class III: No Benefit) 2, 3.

However, the 2024 AHA/ACC guidelines have evolved closer to the Canadian position, now recommending surveillance in elevated-risk patients and acknowledging that elevated postoperative troponin consistently identifies patients at increased mortality risk 4.

Practical Implementation Algorithm

For your specific patient population (age ≥65 or RCRI ≥1):

1. Measure troponin daily for 48-72 hours postoperatively starting on postoperative day 0 or 1
2. Use either conventional fourth-generation or high-sensitivity troponin assays 4
3. Obtain a baseline preoperative value to distinguish acute from chronic elevation 4

If troponin is elevated:

• Obtain ECG to assess for ischemic changes 2, 3, 4
• Evaluate for symptoms (chest pain, dyspnea, hemodynamic instability)
• Consider cardiology consultation - associated with lower 30-day mortality 4
• Intensify cardiovascular medical therapy (aspirin, statins, GDMT) - associated with reduced MACE at 1 year 4
• Exclude nonischemic causes (PE, sepsis, acute HF, stroke) 4

Clinical Pitfalls

• Do not wait for symptoms - most perioperative MIs are silent 1
• Do not screen low-risk patients - troponin surveillance in asymptomatic patients undergoing low-risk surgery is not beneficial 4
• Do not ignore small elevations - even troponin elevations below MI threshold (MINS) increase mortality 3-fold 1, 4
• Recognize the management gap - while detection is proven beneficial, optimal treatment of MINS remains under investigation 1, 4

Supporting Evidence

Meta-analyses demonstrate troponin elevation predicts all-cause mortality (OR 6.7) at 1 year after surgery 1. The number needed to screen ranges from 4.4 to 14 patients to detect one with MACE, depending on risk stratification 5, 6. Perioperative troponin surveillance has been shown to be cost-effective 1.

Bottom line: For patients ≥65 years or RCRI ≥1 undergoing major vascular or intermediate-risk surgery, routine postoperative troponin screening for 48-72 hours is strongly recommended to reduce mortality through early detection and intervention.